U.S. Surgical
This article was originally published in The Gray Sheet
Executive Summary
Eliminates 775 jobs from its Connecticut and Puerto Rico operations in a cost-cutting move, the firm says Oct. 30. Two-thirds (490) of the reductions are voluntary and affect primarily manufacturing positions, while the remaining 285 layoffs involve supervisory and managerial staff at USSC, which was recently bought by Tyco International for $3.3 bil. ("The Gray Sheet" June 1, p. 3). No cuts in the firm's sales force are made. Future reductions at USSC's non-Connecticut operations also are expected, according to the firm, which plans over the next 15 months to consolidate its Norwalk and North Haven, Connecticut, facilities in a single campus at North Haven
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.